A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Inclusion Criteria

- Currently meet the DMS-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th
edition) criteria for Major Depressive Disorder (MDD)

- The participant must have an ongoing major depressive episode of at least 8 weeks and
no more than 18 months

- The participant must have at least 3 lifetime episodes of MDD (including the current
episode)

Exclusion Criteria:

- Women who are pregnant, women who will be breastfeeding during the study, and women
with childbearing potential who are not practicing a reliable method of birth control

- Participants who are considered a suicide risk

- History of non-response to 2 or more antidepressants (after adequate treatment)

- Participants who have a history of meeting DMS-5 criteria for manic, hypomanic, or
mixed episode, obsessive-compulsive disorder, schizophrenia or other psychotic
disorder

- Panic disorder